A Diabetes Drug Called Invokana May Prevent or Slow Kidney Disease, a New Study Says

A drug that’s used to help control blood sugar in people with diabetes has now been shown to help prevent or slow kidney disease, which causes millions of deaths each year and requires hundreds of thousands of people to use dialysis to stay alive. Doctors say it’s hard to overstate the importance of this study, and what it means for curbing this problem, which is growing because of the obesity epidemic. The study tested Janssen Pharmaceuticals’ drug Invokana. Results were discussed Sunday at a medical meeting in Australia and published by the New England Journal of Medicine. About 30 million Americans and more than 420 million people worldwide have diabetes , and most cases are Type 2, the kind tied to obesity. It occurs when the body can’t make enough or properly use insulin, which turns food into energy. This can damage the kidneys over time, causing disease and ultimately, failure. In the U.S., it’s responsible for nearly half a million people needing dialysis, and for thousands of kidney transplants each year. Some blood pressure drugs lower this risk but they’re only partially effective. The new study tested Invokana, a daily pill sold now to help control blood sugar, to see if it also could help prevent kidney disease when added to standard treatments. For the study, about 13,000 people with Type 2 diabetes and chronic kidney disease from around the world were to be given Invokana or dummy pills. Independent monitors stopped the stud...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized medicine onetime overnight Source Type: news

Related Links:

Publication date: Available online 16 April 2019Source: Trends in Anaesthesia and Critical CareAuthor(s): Daniela Godoroja, Massimiliano Sorbello, Michael MargarsonAbstractAirway management is often the major concern of anaesthetists when presented with a morbidly obese patient for general anaesthesia. All anaesthetists are encountering increasing numbers of these patients, presenting for all types of surgery. With the particular experience gained from bariatric surgery worldwide, there is now a greater evidence base to support and guide our practice.This review article aims to provide an update of the key points in safe a...
Source: Trends in Anaesthesia and Critical Care - Category: Anesthesiology Source Type: research
Date: Monday, 04 22, 2019; Speaker: Miranda Broadney , Using FreeStyle Libre Pro Continuous Glucose Monitor in youth , The Yanovski group, DTM, NICHD; Younghoon Jang, Transcriptional regulation of post-natal adipose tissue development, The Ge group, CEB, NIDDK; Building: Building 10 (Clinical Center); Solarium Conference Room 9S233 (old Bunim Room)
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Friday, 05 03, 2019; Speaker: Dr. Rajat Madan, Assistant Professor of Medicine, Infectious Disease Division, University of Cincinatti; Building: Building 40; Videocast Event
Source: NIH Calendar of Events - Category: American Health Source Type: events
Publication date: Available online 16 April 2019Source: Materials Chemistry and PhysicsAuthor(s): Totka Dodevska, Ivelina Vasileva, Petko Denev, Daniela Karashanova, Biliana Georgieva, Daniela Kovacheva, Nikoleta Yantcheva, Anton SlavovAbstractSilver nanoparticles (AgNPs) were synthesized by reduction of Ag+ with four extracts of Rosa damascena waste: post-distillation water (PW), water extract (WE), 30% (30 EE) and 70% (70 EE) ethanol extracts. The ethanolic extracts were rich in polyphenols and particularly catechin and epicatechin (1388.01 ± 2.27 and 677.47 ± 2.03 μgmL−1, respectivel...
Source: Materials Chemistry and Physics - Category: Materials Science Source Type: research
Conclusions The IRRPs are closely related to IR induced by olanzapine, and Pueraria could interfere with olanzapine-associated IR and revert overexpressed IRRPs. These findings suggest that IRRPs are key players in olanzapine-associated IR and that Pueraria has potential as a clinical drug to prevent the metabolic adverse effects of olanzapine, further improving compliance of schizophrenia patients.
Source: Journal of Clinical Psychopharmacology - Category: Psychiatry Tags: Original Contributions Source Type: research
Conclusions We found significantly decreased kidney concentrating ability in the long-term lithium-treated patients compared with the control group. Other renal function markers did not indicate any significant signs of renal dysfunction.
Source: Journal of Clinical Psychopharmacology - Category: Psychiatry Tags: Original Contributions Source Type: research
St. Louis-based Ascension, the nation ’s largest Catholic health care organization, has appointed James Beckmann as CEO and president of Ascension International, effective April 15. In the new role, Beckmann will serve in both governance and management for Ascension’s international entities, including Ascension Ramsay NuSoarceGloba l, Ascension’s global sourcing joint venture with Australia-based Ramsay Health Care. Beckmann replaced John Doyle, who will continue serving in governance roles…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
In conclusion, we demonstrate the first evidence to indicate that lncRNA H19 is associated with PCOS, suggesting that elevated lncRNA H19 levels are a risk factor for PCOS. For susceptible individuals, lncRNA H19 may represent a useful biomarker of the early stages of endocrine and metabolic disorders in PCOS. PMID: 30982795 [PubMed - as supplied by publisher]
Source: Endocrine Journal - Category: Endocrinology Tags: Endocr J Source Type: research
As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of NAFLD which can be characterized as non-alcoholic steatohepatitis (NASH) is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death; it is associated with extrahepatic manifestations such as chronic kidney disease cardiovascular disease and sleep apnea.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Public Health Source Type: research
As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of NAFLD which can be characterised as non-alcoholic steatohepatitis (NASH) is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death. NAFLD is also associated with extrahepatic manifestations such as chronic kidney disease, cardiovascular disease and sleep apnoea.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Public Health Source Type: research
More News: Australia Health | Canagliflozin | Cardiology | Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Dialysis | Eating Disorders & Weight Management | Endocrinology | Epidemics | Epidemiology | Health | Heart | Heart Transplant | Insulin | Insurance | Invokana | Kidney Transplant | Kidney Transplantation | Obesity | Study | Sugar | Transplant Surgery | Transplants | Urology & Nephrology